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Abstract: The incidence of melanoma is rising. The primary initial treatment for melanoma 
continues to be wide local excision of the primary tumor and affected lymph nodes. Exceptions 
to wide local excision include cases where surgical excision may be cosmetically   disfiguring 
or associated with increased morbidity and mortality. The role of definitive or adjuvant radio-
therapy has largely been relegated to palliative measures because melanoma has been viewed as 
a   prototypical radiotherapy-resistant cancer. However, the emerging clinical and radiobiological 
data summarized here suggests that many types of effective radiation therapy, such as radiosurgery 
for melanoma brain metastases, plaque brachytherapy for uveal melanoma, intensity modulated 
radiotherapy for melanoma of the head and neck, and adjuvant radiotherapy for selected high-
risk, node-positive patients can improve outcomes. Similarly, although certain chemotherapeutic 
agents and biologics have shown limited responses, long-term control for unresectable tumors 
or disseminated metastatic disease has been rather disappointing. Recently, several powerful 
new biologics and treatment combinations have yielded new hope for this patient group. The 
recent identification of several clinically linked melanoma gene mutations involved in mitogen-
activated protein kinase (MAPK) pathway such as BRAF, NRAS, and cKIT has breathed new 
life into the drive to develop more effective therapies. Some of these new therapeutic approaches 
relate to DNA damage repair inhibitors, cellular immune system activation, and pharmacological 
cell cycle checkpoint manipulation. Others relate to the investigation of more effective targeting 
and dosing schedules for underutilized therapeutics, such as radiotherapy. This paper summarizes 
some of these new findings and attempts to give some context to the renaissance in melanoma 
therapeutics and the potential role for multimodality regimens, which include certain types of 
radiotherapy as aids to locoregional control in sensitive tissues.
Keywords: hypofractionation radiotherapy, brachytherapy, radiosurgery, melanoma cell cycle, 
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Introduction
Several recent reviews have discussed changes in the systemic management of 
melanoma, including the potential use of newer, more effective biologic agents.1–3 
Because certain types of radiotherapy have also been enjoying a rebirth of enthusiasm, 
we have chosen to focus this review on some of the radiotherapeutic implications of 
multimodality treatment for a clinically heterogeneous disease. We call attention to 
the fact that older therapeutic modalities, such as radiation, previously consigned 
to the melanoma scrap heap as ineffective, may still have a significant role in the 
future. Furthermore, as our understanding of the biological mechanisms of melanoma 
  tumorigenesis increases and we find ways to exploit these mechanisms biologically, 
it is likely that the role of radiation therapy will continue expanding beyond what is OncoTargets and Therapy 2011:4 submit your manuscript | www.dovepress.com
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currently being done. In addition, differences in the molecular 
and biological makeup of cutaneous melanomas compared 
with that of retinal or mucosal melanoma may also help in 
further tailoring radiotherapy fractionation and technical 
approaches in the future.
In their classic 1946 text, McKee and associates4 opine 
that “in spite of occasionally good results, it is our opinion 
that irradiation alone by any technique should not be relied 
on for the cure of these lesions”. This reputation as one of 
the least radioresponsive and least radiocurable tumors has 
dogged melanoma since the early days of orthovoltage x-ray 
treatments for skin conditions. In the modern era, many 
investigators are beginning to question the accuracy of this 
reputation.5–9 In fact, in vitro data on melanoma cell lines are 
generally acknowledged to show high levels of DNA damage 
repair at conventional fractionation doses and increased cell 
death with larger doses per fraction. A popular hypofraction-
ated regimen involving a dose of 7 Gy per fraction delivered 
on days 1, 7, and 21 for postoperative patients demonstrated 
complete remission rates of 40%, with greater than 90% 
local control rates at four years.5 Some of the radioresistance 
based on recently reported in vivo biological data from mice 
  suggests that a radiation-induced decrease in substance P may 
partly explain the radioresistant nature of some melanoma 
cell lines,10 and that altered fractionation regimens may be 
needed to overcome this based on clinical studies.5
Although the trends to utilize radiotherapy have been 
slow to catch on, recent evaluations suggest that the 
reputation of malignant melanoma as a “radioinsensitive” 
disease may not be entirely justified. As such, the role of 
radiotherapy in the future will likely continue to grow in 
light of novel emerging biologic agents which have yet to 
be investigated in the concurrent combined multimodality 
setting. This review summarizes some of the clinical and 
radiobiological evidence for the role of radiotherapy and 
will focus on four relatively new areas of clinical growth, 
ie, intracranial radiosurgery, retinal plaque brachytherapy, 
intensity modulated radiotherapy for mucosal melanoma of 
the head and neck region, and lymphatic field radiotherapy for 
node-positive, surgically debulked cases. For some of these 
clinical   situations, it appears that moderate dose radiotherapy 
may be considered a viable option to surgery (intracranial 
metastases, uveal melanoma, mucosal melanoma of the head 
and neck) and as an adjunct in others. Here we also discuss 
some of the biological understanding behind malignant 
transformation of melanoma and then focus on some of the 
emerging targeted systemic options which provide increased 
optimism for radiotherapists in the future.
Epidemiology
Melanoma has the fastest growing incidence of any   cancer 
among men, and the second fastest growing incidence 
among women.11 In 2010, melanoma will be responsible for 
68,130 new cases and 8700 deaths, and is the fifth and sixth 
  leading cause of cancer in men and women, respectively.12 
The lifetime risk for the development of melanoma is one 
in 39 for men and one in 58 for women, with Caucasian 
men being at the highest risk.12 The median age at diagnosis 
is 59 years, peaking during the fourth and fifth decades. At 
diagnosis, 82%–85% will have localized disease, 10%–13% 
will have regional disease, and 2%–5% will have nonregional 
metastatic disease.13 The five-year survival rates are 98% if 
localized, 62% if regional, and 15% if metastatic.11 The five-
year overall survival rates have increased over the decades, 
from 82% in 1975–77, to 87% in 1984–86, and to 92% in 
2004.12 The increase in overall survival is partly attributed 
to earlier detection as a result of increased education and 
public awareness.14
Surgical excision
The primary treatment of skin melanoma continues to be 
wide local excision. Sentinel node biopsy with lymph node 
dissection is reserved for advanced infiltrative lesions at high 
risk for spread to regional lymph nodes. Patients considered 
most appropriate for sentinel node biopsy include stage 
IB, stage II with a # 1 mm thick lesion and ulceration or 
mitotic rate $ 1 /mm2, stage II with a . 1 mm thick lesion, 
and resectable stage III tumors with in transit metastases.15 
The extent of wide local excision has been evaluated in 
several large-scale randomized clinical trials. The contro-
versy has revolved around the margins of excision. A trial 
from France determined that for melanomas with Breslow 
depth , 2.1 mm, there was no difference in 10-year overall 
survival between a 2 cm and a 5 cm excision margin.16 The 
findings using narrower margins for surgical resection have 
been confirmed in other randomized trials17–19 as well as in a 
more recent study from the UK.20 These randomized   studies 
have served as the basis for the current National Cancer 
Center Network guidelines15 (Table 1).
Historical management: limited  
role for conventional radiotherapy
Historically, melanoma was considered highly   radioresistant. 
Simpson in 1913 was one of the first to treat a black nevus 
with radiation successfully and with little damage of 
  surrounding skin.6 His approach was considered unwise due 
to concerns about toxicity.21 Controversy over the role of OncoTargets and Therapy 2011:4 submit your manuscript | www.dovepress.com
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radiotherapy continued until two landmark studies provided 
convincing evidence to support Simpson. Ellis in 1939 treated 
38 patients using 55–60 Gy over 7–10 days and demonstrated 
a good response in 12 patients.6,22 The second study in 1963 
reported on the 25-year experience, and demonstrated that 
the five-year overall survival was 68% in 95 patients, with 
results that equaled surgery.6,23 Despite the promise of these 
earlier studies, advances in infection control and anesthesia 
led to improved surgical morbidity and mortality, and surgery 
became the preferred therapy. Radiation use waned until the 
1970s when reports of melanoma radiobiology suggested 
that melanoma cells were heterogeneous, not universally 
radioresistant.6,9,24
The first prospective randomized trial was published in 
1991 by the Radiation Therapy Oncology Group (RTOG 
83-05).25,26 The trial tested the earlier radiobiological findings 
that a higher radiation dose per treatment is needed to control 
melanoma by comparing a hypofractionated group receiving 
8 Gy per fraction in four treatments delivered over 21 days 
with a standard group receiving 2.5 Gy per fraction in 20 
treatments delivered five days a week over 26–28 days. The 
trial demonstrated an overall response rate of 57%–60%, but 
failed to show a difference between the different fractionation 
regimens. Furthermore, the overall response rate of around 
60% was much lower than the previously reported response 
rates of 97% comparing 9 Gy in three fractions with 5 Gy in 
eight fractions delivered twice a week.25 Thus, RTOG 83-05 
was closed prematurely.
In contrast with RTOG 83-05, several retrospective studies 
have reported that a large fraction size was linked to improved 
response rates, confirming earlier radiobiological findings.27 One 
study of 35 patients (67 cutaneous or lymph node metastases) 
showed a complete response of 9% if #5 Gy per treatment was 
used and 50% if radiation doses $ 5 Gy per treatment were 
used.28 Another study from 1983–1988 demonstrated 2-year 
locoregional control of 95% in head and neck melanoma patients 
presenting with clinically negative lymph nodes treated with 
larger doses of adjuvant radiation (24–30 Gy in 4–5 fractions 
at 5–6 Gy per fraction) to the tumor bed and regional lymph 
nodes. The authors concluded that locoregional control rates 
were better than surgery alone for comparable patients and 
that treatment morbidity with the addition of hypofractionated 
radiation was minimal.29
Recent growth in role  
of radiotherapy
Since the 1970s, radiotherapy has been used more frequently 
to treat melanoma, particularly in areas where surgical 
excision has had limited success for cosmetic reasons or 
morbidity of the surgical procedure itself. Areas of recent 
growth include radiosurgery for brain metastases, plaque 
brachytherapy for uveal melanoma, and intensity modulated 
radiotherapy for head and neck melanoma. Furthermore, 
there is likely to be an increase in the use of adjuvant radio-
therapy for selected high-risk patients with recurrent node-
positive disease based on newer clinical data which suggests 
improved progression-free survival with the use of postopera-
tive radiotherapy for selected high-risk patients.30,31
We have already witnessed a change in the referral 
  patterns at our institution. This growth is a direct result 
of greater clinical and radiobiological understanding of 
the response of melanoma to radiotherapy, and   delivering 
hypofractionated radiotherapeutic regimens in a much 
more   conformal way. As we continue to learn more about 
the differences in the natural history and biology of retinal 
versus cutaneous and mucosal melanoma, radiotherapy may 
continue to be further refined in the future. For example, 
the natural history of uveal melanoma dictates radiotherapy 
focused only to the primary site, whereas radiotherapy for 
mucosal melanoma of the head and neck region may   dictate 
radiotherapy to the primary site as well as the regional 
lymphatics. Lastly, the use of local radiotherapy only to the 
primary site versus treating the local site plus the lymphatic 
regions for cutaneous melanoma is a function of stratifying 
patients into low risk versus high risk for regional recurrence 
based on particular clinical and biological indicators.
Radiosurgery and whole brain 
radiation
The brain is a common site of melanoma metastasis, with 
brain metastases contributing to 20%–54% of all deaths.32 
Patients at increased risk for brain metastases include 
males, patients with head and neck mucosal melanomas, 
and lesions with metastases to $3 regional lymph nodes.33 
These late-stage patients with brain metastasis generally have 
a poor prognosis, and treatment options are limited. Chemo-
therapy is generally ineffective. However, radiotherapy can 
Table  1  Guidelines  for  surgical  excision  of  melanoma,  from 
the  National  Cancer  Center  Network  Practice  Guidelines  in 
Oncology15
Tumor thickness Recommended margins
in situ 0.5 cm
,1.0 mm 1.0 cm
1.01–2 mm 1–2 cm
2.01–4 mm 2.0 cm
.4 mm 2.0 cmOncoTargets and Therapy 2011:4 submit your manuscript | www.dovepress.com
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get beyond the meninges and provide targeted high-dose 
treatment, making it a valuable weapon in the arsenal against 
melanoma brain metastases.
Radiotherapy options for brain metastases include 
  stereotactic radiosurgery alone, whole brain radiotherapy 
with or without stereotactic radiosurgery, and postopera-
tive whole brain radiotherapy. Several retrospective studies 
have shown the efficacy of both linear accelerator-based 
  stereotactic radiosurgery (LINAC-SRS) as well as gamma 
knife-based radiosurgery. These studies are summarized in 
Tables 2 and 3 and have demonstrated 1-year local control 
rates of 49%–90% with both LINAC-SRS and gamma 
knife-based radiosurgery.34–37 Stereotactic radiosurgery 
also improves quality of life while reducing symptoms 
such as headaches, seizures, and visual disturbances.38 
Lastly, stereotactic radiosurgery may also improve overall 
survival by 7.3 months when combined with whole brain 
radiotherapy.39
Plaque brachytherapy for uveal 
melanoma
Uveal melanomas arise in the choroid, ciliary body, or iris. 
Their molecular pathogenesis is distinct from that of the 
cutaneous melanomas. Instead of a BRAF, NRAS, or cKIT 
mutation, 83% of uveal melanomas have a   mutation at the 
GNA11 or GNAQ loci.40,41 These genes encode   heterotrimeric 
G proteins which, through downstream effects, upregulate 
the mitogen-activated protein kinase pathway in   melanocytes 
when activated. G proteins   generated from the mutant 
genes lose their GTPase activity and are   constitutionally 
activated.42
Historically, uveal melanomas were treated with enucle-
ation. The Collaborative Ocular Melanoma Study random-
ized 1317 patients with medium-sized choroidal melanomas 
(2.5–10.0 mm in apical height and 5–16 mm in largest 
basal diameter) to enucleation or iodine-125 brachytherapy 
and found no difference in 5-year survival rates (81% for 
enucleation and 82% for brachytherapy, P = 0.48).43 Plaque 
brachytherapy (Figure 1) has evolved into a promising 
  alternative to enucleation by providing equivalent overall 
survival with a better chance of long-term visual preservation 
and improved cosmetic outcomes.
The next step in uveal melanoma treatment may be the 
use of novel biologic agents. Just as the BRAF inhibitor, 
PLX4032, successfully treated patients with cutaneous mela-
nomas, a MEK inhibitor may produce similar tumor shrink-
age and improve the survival of uveal melanoma patients.40 
The role of a MEK inhibitor when combined concurrently 
with radiation therapy is yet to be investigated in a random-
ized clinical trial.
Mucosal head and neck melanoma
Primary mucosal melanomas of the head and neck region 
have less than a 30% 5-year survival rate.44 A retrospective 
review of 48 patients treated with surgery alone, surgery 
and adjuvant radiotherapy, or surgery and biochemotherapy 
(with or without adjuvant radiotherapy) showed that radiation 
therapy decreased local failure rates, but without impacting 
overall survival. The lack of benefit in overall survival was 
due to the high rate of distant metastases.45 Another retro-
spective review of 69 patients, with 23% reporting lymph 
node involvement, reviewed the results of 30 patients who 
had surgery alone and 39 patients who had postoperative 
radiotherapy (70 Gy in 29 patients and 50 Gy in 10 patients). 
Local control was improved in patients who received adju-
vant radiation treatment, but survival rates were worse. The 
patients who received radiotherapy developed significantly 
more systemic metastases, but on multivariate analysis this 
was ascribed to a more advanced tumor and nodal classifica-
tion in the radiotherapy group.44
Recent case reports have addressed the differences in 
molecular mutations between melanomas occurring in 
chronic sun exposed regions (infrequent BRAF and NRAS 
and increased cKIT mutation) compared with those in regions 
not exposed to sun,46 and have suggested that treatment with 
imatinib, a c-KIT inhibitor, may provide additional optimism.47 
Table 2 Role of linear accelerator stereotactic radiosurgery in the treatment of melanoma brain metastases
Study Patients (n) One-year LC One-year OS Comments
Mori et al34 60 90% 7 months improved survival on multivariate analysis included lack of 
active systemic disease and at least one metastasis.
51 (wBRT + SRS)
Selek et al35 103 49% 6.7 months 75% LC for tumors , 2 cm with initial SRS alone
61 (SRS) 60% 7.5 months
12 (SRS + wBRT) 0% 3.7 months
30 (SRS after wBRT) 37% 5.4 months
Abbreviations: LC, local control; OS, overall survival; SRS, stereotactic radiosurgery; wBRT, whole brain radiotherapy.OncoTargets and Therapy 2011:4 submit your manuscript | www.dovepress.com
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Using molecular biology to develop a tailored   multidisciplinary 
combined approach is an area of ongoing research.
Control of lymph node-positive 
disease
Although earlier studies48 suggested adjuvant radiation 
therapy for melanoma was ineffective, newer studies suggest 
better local and regional control in selected high-risk patients. 
Patients with desmoplastic histology, positive margins, 
recurrent disease, and/or a . 4.0 mm Breslow lesion with 
ulceration or satellitosis are at high risk for local recurrence 
and may benefit from adjuvant radiotherapy to the local 
site.49 Patients with at least four lymph nodes, extracapsular 
extension, lymph node size $ 3 cm, cervical lymph node 
involvement, sentinel lymph node involvement but without 
complete lymph node dissection, and recurrent disease are at 
high risk for nodal relapse and may benefit with radiotherapy 
to the nodal basins.49–51 Further progress in this arena would 
be welcomed, because postsurgical recurrence in the nodal 
basins is associated with lower survival rates.30
A Phase II study of 48 Gy in 20 fractions to the nodal 
basins after surgery showed impressive regional control 
compared with historical cohorts.30 The study enrolled 
234 patients with disease in three nodal basins (head and 
neck, axilla/supraclavicular, and ilioinguinal). The authors 
  demonstrated a low infield recurrence rate (7%), a low adja-
cent relapse rate (14%), and an impressive 5-year regional 
control rate of 91% with use of adjuvant radiotherapy. 
However, the 5-year overall survival rates (36%) and 
progression-free survival rates (27%) continued to be dismal 
due to uncontrolled systemic metastases.30 The side effects 
after radiotherapy were minimal and radiotherapy was well 
tolerated. The recommended postoperative radiation fields30 
are shown in Figure 2.
This Phase II study was followed by a multicenter Phase 
III trial.31 The trial included post lymphadenectomy patients 
with isolated regional recurrence who were deemed to be 
high-risk (.25%) for further regional recurrence (one or 
more parotid lymph nodes, at least two cervical or axillary 
lymph nodes, at least three groin nodes, any extranodal spread 
of melanoma, or maximum metastatic node diameter $ 3 cm 
in neck or axilla, or $4 cm node in the groin). Two hundred 
and fifty patients were randomly assigned to observation 
versus regional radiation therapy using 48 Gy in 20   fractions 
delivered at 2.4 Gy per fraction. The study showed that 
postoperative radiation resulted in improved disease-free 
survival (hazard ratio [HR] 1.77 with P = 0.041).31 Others 
have also recommended the use of adjuvant radiotherapy 
after therapeutic lymphadenectomy for patients with a high 
risk for recurrence in the nodal basin.52,53
Malignant transformation
Several aberrant genes are implicated in the pathogenesis 
of malignant melanoma:54,55 BRAF (enhances cell division); 
N-RAS (promotes cell proliferation); MITF overexpression 
(promotes survival and inappropriate cell cycle progression); 
c-KIT (involved in invasion and metastases); SLUG (involved 
in metastases); and EDNRB (involved in invasiveness). 
Alternatively, loss of tumor suppressor CDKN2A (encoding 
p16INK4a and ARF, that are involved in cell cycle progression), 
E-cadherin (CDH1, involved in tumor progression), and p53 
(TP53 gene, playing a role in response to DNA damage) 
Table 3 Role of gamma knife-based radiosurgery in the treatment of melanoma brain metastases
Study Patients (n) One-year LC One-year OS Comments
Yu et al36 122 90% 7 months improved survival on multivariate analysis = total intracranial 
tumor volume , 3 cm3, inactive systemic disease
Radbill et al37 51 81% 26 weeks
GKRS alone = 32
Abbreviations: GKRS, gamma knife-based radiosurgery; OS, overall survival.
Figure 1 iodine125 plaque brachytherapy for a patient with an iris melanoma.OncoTargets and Therapy 2011:4 submit your manuscript | www.dovepress.com
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may also play a role in the radioresistance of some human 
melanoma cell lines.56
The movement of cells through the cell cycle is regulated 
by sequential expression of cyclins and activation of their 
catalytic partners, cyclin-dependent kinases. For example, 
cyclin D, which regulates the transition from the G1 to S 
phase, binds to and activates the cyclin-dependent 4 and 
cyclin-dependent 6 kinases. These complexes phosphorylate 
the retinoblastoma protein, which disassociates from E2F 
and allows E2F to activate transcription of critical DNA 
synthesis genes and cyclins, such as cyclin E, facilitating 
progression into the S phase of the cell cycle (Figure 3).57–59 
Important regulators of this pathway are inhibitors of 
the cyclin-dependent kinases, ie, CDKN1A (p21/WAF1, 
  activated primarily by p53) and p16, which complexes with 
cyclin-dependent kinases 4 and 6 and prevents phosphoryla-
tion of retinoblastoma protein, as well as ARF (CDKN2A), 
leading to inhibition of p53 degradation via the ubiquitin 
ligase hDM2.
An alternative pathway implicated in cell survival and 
increased reproduction involves the mitogen-activated protein 
kinase signaling cascade (Figure 3). ERK1/2 in this pathway 
relays the proliferative/cell survival signals via various targets 
that provide cross-talk with cell cycle (cyclin D, RBL2/p130, 
Myc) or cell survival (Bim, Mcl-1) regulators (Figure 3).56,60 
The PI3K-AKT pathway is also critical, with more than 60% 
of human melanomas e  xhibiting activated AKT, and inactiva-
tion and/or deletion of the PI3K   negative regulator (PTEN) 
Figure 2 Post surgical radiation fields for node positive patients.
Reprinted from Burmeister BH, Mark Smithers B, Burmeister e, et al. A prospective phase ii study of adjuvant postoperative radiation therapy following nodal surgery 
in malignant melanoma–Trans Tasman Radiation Oncology Group (TROG) Study 96.06. Radiother Oncol. 2006;81:136–142. Copyright © 2007, with permission from 
elsevier.30OncoTargets and Therapy 2011:4 submit your manuscript | www.dovepress.com
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Figure 3 Cell survival signals and potential therapeutic targets for malignant melanoma.
occurring in 5%–15% of uncultured melanoma specimens 
and metastasis, 17% of short-term melanoma cultures, and 
30%–40% of established melanoma cell lines.61
Melanoma mutations: future  
targets and hypofractionated 
radiotherapy
A better understanding of the role played by cyclin-  dependent 
kinases in cell cycle blocks is particularly important, 
because these molecules are also involved in controlling and 
  modifying the radioresponse of melanoma cells (Figure 3). 
By controlling cyclin-dependent kinases, one can develop a 
mechanism to explain the relative radioresistance of different 
melanoma cell lines and provide radiobiological evidence 
as to why either higher doses of radiation may overcome 
potentially lethal damage repair or how radiation may be 
combined with the newer biological agents.
The p16-Rb tumor suppressor pathway is required for the 
initiation and maintenance of cellular senescence. Senescence 
can be overcome if the pathway is not fully engaged, as may 
occur when p16 is inactivated.62 p16 can initiate a cyclin-
dependent kinase 4/6-dependent autonomous senescence 
program that is disabled by inherited melanoma-associated 
mutations.62 As more knowledge is obtained regarding aber-
rant components of the cell cycle regulatory circuit leading to 
melanoma development, therapeutic trials targeting specific OncoTargets and Therapy 2011:4 submit your manuscript | www.dovepress.com
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mutant proteins are getting underway. For example, one study 
using human melanoma cancer cell lines cultured in vitro 
and in mice in vivo showed that selective and structurally 
distinct small molecular inhibitors of cyclin-dependent 
kinase 4 and cyclin-dependent kinase 6 resulted in increased 
cellular radioresistance, especially in those cancer cell lines 
dependent on the cyclin-dependent kinase 4/6 pathway for 
proliferation. In contrast, cyclin-dependent kinase 4/6 inhibi-
tors did not protect cell lines that proliferated independently 
of cyclin-dependent kinase 4/6 activity.63
Sorafenib is a Raf tyrosine kinase inhibitor that inhibits 
the mitogen-activated protein kinase pathway (Figure 3) in 
vitro and in vivo. It has antiangiogenic effects and has been 
effective in treating cancers with and without BRAF muta-
tions, making it a promising adjuvant therapy for melanoma.60 
Because the majority of melanomas harbor an activating 
missense mutation (V600E) in the BRAF oncogene, targeted 
inhibition of the V600E gene product is an important thera-
peutic goal.64 Pharmacologic inhibition of oncogenic BRAF 
blocks proliferation and causes tumor regression. A Phase I 
trial of PLX4032, an oral inhibitor of V600E-mutated BRAF, 
demonstrated complete or partial tumor regression in 81% of 
patients and improved median progression-free survival from 
2.0–6.2 months for patients with metastatic melanoma.65
Current research is exploring the use of adjuvant thera-
pies targeted at normal cells to reduce the toxicity of cancer 
treatments.66 These therapies suppress apoptosis in healthy 
cells by inhibiting p53, activating NF-κB, and preventing cell 
cycle progression by preventing the cyclin-dependent kinases 
from complexing with cyclin D.66 Conversely, targeting the 
cell cycle control pathway components in tumor cells when 
combined with hypofractionated radiotherapy protocols 
may further improve the radioresponsiveness of melanoma. 
In addition to being highly active in melanoma cells, the 
COX-2, P13K-AKT, and NF-κB pathways are also involved 
in the radioprotective response. It has been shown recently 
that Ink4a/Arf–/– mice with melanocyte-specific deletion 
of Ikkβ were protected from H-RasV12-initiated melanoma 
when p53 was expressed, providing genetic and mechanis-
tic evidence that mutant H-Ras initiation of tumorigenesis 
requires Ikkβ-mediated NF-κB activity.67 Suppressing those 
pathways pushes higher numbers of melanoma cells into 
the mitotic phase, which is the most radiosensitive phase in 
the cell cycle, leading to decreased overall melanoma cell 
survival.68 One study compared the radiosensitivity of cells 
expressing wild-type p16 with those having the mutant p16 
found in melanomas, and found that the melanoma cells were 
less sensitive to x-ray irradiation if they had a p16 mutation.69 
Therefore, an adjuvant therapy targeting the expression of 
mutant p16 would not only lead to better cell cycle regulation, 
but render the melanoma cells more radiosensitive.
A recent randomized trial of ipilimumab evaluated the role 
of an antibody targeting CTLA-4 in HLA-A*0201-positive 
unresectable stage III/IV melanoma patients who progressed 
on chemotherapy, and showed a significant improvement in 
median overall survival (10.0 months versus 6.4 months, 
P , 0.0001).70 Radiotherapy effects on the cellular immune 
system, or abscopal effects, may be partially responsible for 
the apparent positive impact on node-positive melanoma. 
Irradiated tumor tissues may develop inflammation leading 
to improved immune system activation, and how this can be 
utilized to make the emerging biologics more effective is an 
area of ongoing research.71
Areas for future research  
and growth
Concurrent chemoradiotherapy
Currently, the only approved chemotherapy for metastatic 
melanoma is the oral equivalent of dacarbazine, ie, temozo-
lomide, which has a response rate of about 10% and a median 
survival of 8–9 months.72 Concurrent use of temozolomide 
with radiotherapy is the standard care for patients with glio-
blastoma multiforme, because this combined approach has 
shown increased efficacy over either approach alone. The 
combined approach of temozolomide given concurrently 
with radiation therapy has been tested for melanoma with 
mixed results.73
Concurrent immunoradiotherapy
Other approved agents for advanced melanoma include high-
dose interleukin-2, but only one in 20 patients receives last-
ing benefits with the use of interleukin-2.72 Interleukins are 
cytokines, similar to interferons (IFNs), in that they are potent 
modulators of the immune system. IFN-α, a type I IFN, fre-
quently used as adjuvant therapy for melanoma, is synthesized 
in vivo to respond to a viral infection and to kill tumor cells.74 
By binding to its cell receptor, IFN-α activates the transcrip-
tion factor ISGF3, which then activates the IFN-stimulated 
response element in the promoter sequence of the p53 gene. 
Activation of the IFN-stimulated response element induces 
p53 production, leading to increased apoptosis of the tumor 
cells.75,76 Adjuvant IFN can improve relapse-free survival in 
high-risk patients and patients with low-risk to intermediate-
risk disease without impacting overall survival.77 Improve-
ments in local recurrence without impact on overall survival 
have also been demonstrated in other studies.51,78 Only one OncoTargets and Therapy 2011:4 submit your manuscript | www.dovepress.com
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study of 287 patients with melanomas . 4.0 mm and/or one 
regional metastasis randomized to either adjuvant therapy with 
high-dose IFN-α 2b for 1 year or to observation, demonstrated 
an improvement in both disease-free survival (1.0 years versus 
1.7 years P = 0.0023) and overall survival (2.8 years versus 
3.8 years, one-sided P = 0.0237) at 6.9 years of follow-up.79 
This was not replicated in a subsequent randomized trial by the 
same group for stage IIB and III patients.80 Consequently, the 
use of IFN as an adjuvant therapy is under debate for patients 
who have progressed to Stage II or beyond.
Case reports have shown significant tumor regression when 
IFN therapy was combined concurrently with radiotherapy for 
large unresectable sinonasal melanoma.81 The combination 
approach has raised concerns about increased toxicity.82,83 One 
small study of 10 patients demonstrated a possible increase in 
subacute and late complications when radiation is delivered 
concurrently with IFN   therapy.84   However, this concern is not 
shared by others who strongly advocate   evaluating a   combined 
approach in future protocols,85 and state that   concurrent 
radiation and IFN therapy may be safely delivered under 
  appropriate clinical monitoring.82
Concurrent bioradiotherapy
Several clinical advances in the past decade have led to 
new treatment strategies, including agents targeted against 
mutations in B-Raf (PLX4032 and sorafenib) and c-KIT 
(kinase inhibitors such as imatinib), T cell immunotherapy, 
removal of immunologic inhibition at checkpoints in T cell 
activation (anti-CTLA 4 antibody), and many others.72,86 
Many of these compounds have yet to be combined with 
radiation in the clinical setting, and represent an area of 
future research.
Recent studies in mouse models have suggested that radia-
tion is more effective when combined with   immunotherapy.87 
A study by Lugade et al demonstrated that radiation to 
tumors in mice resulted in an increase in IFN-γ, allowing for 
a more effective cytotoxic T cell-mediated response against 
melanoma tumor cells. The authors concluded that radiation 
improved the lytic sensitivity of the tumor cells to cytotoxic 
T cells by increasing apoptosis-inducing STAT1 activation, 
and suggested that localized irradiation should be combined 
with emerging immunotherapy in the future.87 Similarly, 
another recent preclinical study demonstrated that radiation 
is a powerful agent in improving synthetic dsRNA therapy for 
an in vivo mouse melanoma model.88 Lastly, a recent study 
by Khan et al demonstrated that riluzole, an inhibitor of glu-
tamate release by human GRM1-expressing melanoma cells, 
enhanced radiosensitivity in melanoma cells in vitro and in 
vivo.89 Khan et al currently have a Phase I protocol underway 
for patients with melanoma brain metastases to test the role 
of combining riluzole with whole brain radiation.
Conclusion
Although it appears true that malignant melanoma is a 
relatively radioinsensitive tumor type, the use of favorable 
fractionation schemes and treatment delivery plans com-
bined with greater radiobiological understanding may 
provide increased local control in certain clinical situations. 
  Intracranial radiosurgery and stereotactic radiotherapy 
appear to provide control rates for melanoma on a par 
with that seen for other more sensitive epithelial tumors. 
Small and medium choroidal melanomas show a natural 
history in which metastasis outside the eye is unusual, thus 
validating the apparent safety of protracted tumor response 
to brachytherapy which produces acceptable levels of visual 
field sparing as an alternative to surgical enucleation. Finally, 
recent Phase III data have shown significant improvements 
in local control after lymphatic radiotherapy for recurrent 
node-positive post-lymphadenectomy patients. For all 
of these clinical scenarios, it appears that a concentrated 
highly   targeted radiation dose, with minimal fractionation 
and   normal tissue inclusion, represents some of the keys to 
restoring confidence in the importance of this therapeutic 
modality for malignant melanoma.
Recent molecular biological understanding suggests 
that malignant melanoma deposits, long known to pro-
liferate primarily in ultraviolet-exposed body surfaces, 
have evolved multiple overlapping protective mechanisms 
capable of activating or suppressing master gene panels 
controlling the dynamics of cell cycle progression in the 
face of cellular or chromosomal damage. Among these 
top-line damage sensor and repair pathways are p53, ATM, 
NF-κB, and components of the cyclin/cyclin-dependent 
kinase regulatory network. The reversal or slowing of some 
of these protective pathways via genetic modifications (eg, 
targeted mutations) or pharmacologic inhibitors (eg, p53 
or p16 small molecule inhibitors) perhaps in combination 
with appropriately fractionated radiotherapy and perhaps 
immunotherapy and chemotherapy may finally transform 
melanoma from the most lethal to one of the most curable 
of the primary cutaneous malignancies.
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